Deerfield Management Company
Deerfield Management Company, founded in 1994, is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy. The firm aims to achieve cures for diseases, improve quality of life, and reduce the cost of care. As of December 2023, Deerfield manages over $14.6 billion in assets and maintains a portfolio of more than 200 private and public investments across various healthcare sectors.
Deerfield Management Company
What We Do
Supporting companies across the healthcare ecosystem with flexible funding models and value beyond capital.
Delivering market research to the Deerfield team, its portfolio companies, and other partners.
A New York City-based not-for-profit devoted to advancing innovative healthcare initiatives.
A 12-story innovation campus in New York City that brings together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.
Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.
Portfolio
Advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases.
#Therapeutics
Delivers evidence-based, virtual PTSD treatment to help trauma survivors find lasting peace and healing.
#Healthcare Services and IT
Reimagining the future of veterinary care through its 'connected care' model, blending modern de novo facilities with 24/7 app-based virtual care.
#Healthcare Services and IT
Dedicated to transforming the treatment of life-threatening invasive fungal infections with a next-generation polyene antifungal designed for reduced toxicity.
#Therapeutics
Advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies.
#Therapeutics
Developed a novel technology platform for fully bioresorbable sirolimus coated vascular scaffolds.
#Medical Technologies
Focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices.
#Therapeutics
Leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria.
#Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression.
#Therapeutics